The Cholesterol Treatment Trialists Collaboration (CTT), based at Oxford University and headed by Sir Rory Collins, has been very influential in shifting UK health policy, which this year started to recommend statin use for all over-60s.
The new guidelines, issued by NICE (National Institute for Health and Care Excellence), followed the publication of 'independent' studies from CTT that maintained that statins had few side effects but many major benefits. Sir Rory was also highly critical of studies published in the British Medical Journal that claimed the drugs caused side effects in 22 per cent of users. He demanded that the papers were retracted, which an independent review panel refused to do.
All along, Sir Rory claimed that he and the CTT were independent, and that any funding came from charitable sources such as the British Heart Foundation and Cancer Research UK. Even as recently as last March, Sir Rory repeated in an email to the BMJ that the British Heart Foundation was a major funder, and demanded to know who had funded the critical research he wanted withdrawn.
But these have been minor funders of CTT and its parent body, the Clinical Trial Service Unit (CTSU). Over the past 20 years, the two research bodies have received lb268m donations, including lb217m from Merck, a major manufacturer of statins.
The true picture came to light only after nutritionist and wholefood campaigner Zoe Harcombe uncovered the original documents that outline the CTSU's funders.